Biodesix Inc
$ 23.50
6.33%
07 Aug - close price
- Market Cap 247,951,000 USD
- Current Price $ 23.50
- High / Low $ 23.93 / 22.45
- Stock P/E N/A
- Book Value -0.30
- EPS -3.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -5.40 %
- 52 Week High 25.00
- 52 Week Low 5.26
About
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$32.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-04 | 2026-02-26 | 2025-11-03 | 2025-08-07 | 2025-05-13 | 2025-03-03 | 2024-11-01 | 2024-08-07 | 2024-05-08 | 2024-03-01 | 2023-11-07 |
| Reported EPS | -0.71 | -0.81 | -0.49 | -1.16 | -0.08 | -1.6 | -0.06 | -1.4 | -1.6 | -2.8 | -0.1 | -2.8 |
| Estimated EPS | -0.86 | -1.1 | -1.05 | -1.51 | -0.07 | -1.4 | -0.0667 | -1.52 | -1.84 | -2.87 | -0.11 | -3 |
| Surprise | 0.15 | 0.29 | 0.56 | 0.35 | -0.01 | -0.2 | 0.0067 | 0.12 | 0.24 | 0.07 | 0.01 | 0.2 |
| Surprise Percentage | 17.4419% | 26.3636% | 53.3333% | 23.1788% | -14.2857% | -14.2857% | 10.045% | 7.8947% | 13.0435% | 2.439% | 9.0909% | 6.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDSX
2026-08-08 14:41:41
Biodesix, Inc. (NASDAQ:BDSX) recently released its quarterly results, showing better-than-expected revenues of US$27m and smaller statutory losses of US$0.71 per share. Following these results, analysts have updated their forecasts for 2026, predicting revenues of US$111.5m and reduced losses per share. This positive outlook has led to a 5.9% increase in the consensus price target to US$32.67, with the company expected to grow faster than its industry.
2026-08-07 18:40:08
Biodesix Inc. (Nasdaq: BDSX) reported improved top and bottom lines in the second quarter, indicating progress towards profitability. The life-sciences company, which specializes in lung diagnostic tools, has shown consistent efforts to boost sales and reduce losses. This financial improvement positions Biodesix on a clearer path toward achieving profitability.
2026-08-06 23:41:41
Biodesix, Inc. (BDSX) has seen its average 12-month price target increased by analysts from $30.83 to $32.67, suggesting a potential 43% upside based on the Aug. 5 closing price. The consensus rating from 7 analysts remains a "Buy," with all seven recommending the stock.
2026-08-06 23:40:07
Biodesix (BDSX) shares dropped almost 3% despite a positive earnings report showing narrowed losses and strong gross margins. While the company is still operating at a loss, its Q2 2026 revenue increased by 34% and net loss narrowed by 37%, with gross margins holding at 82%. The article discusses both bull and bear cases, focusing on execution milestones, primary care growth, and ongoing risks like reimbursement uncertainty.
2026-08-06 11:40:08
Biodesix, Inc. announced an impairment loss on intangible assets for the second quarter ended June 30, 2026. The reported impairment loss was $12,000, a decrease from $26,000 in the same period last year. This information was released on August 5, 2026, as part of their financial reporting.
2026-08-05 21:04:58
Biodesix, Inc. (BDSX) reported a Q2 loss of $0.71 per share, which beat the Zacks Consensus Estimate of a $0.86 loss, marking a 17.44% surprise. The company's revenues for the quarter reached $26.86 million, exceeding estimates by 2.92% and showing growth from $20.02 million a year ago. Biodesix has consistently surpassed EPS and revenue estimates over the last four quarters, and its stock has seen a significant 234.6% increase year-to-date.
